bi-specific anti-Her3 Zybodies (Zyngenia)

N/A

Report date: 2025/03/14 16:36:21

Base Information

Drug Namebi-specific anti-Her3 Zybodies (Zyngenia)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody +[4]

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZyngenia Inc

China Registration ClassN/A

Develop Information

Active CompaniesZyngenia Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A